GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Molecular Dx Has Your (Copy) Number
CNV Detection and Analysis Tools Are Being Used To Fill Genetic Diagnostic Gaps
Despite delays by the FDA and some opposition from originator companies, biosimilars now represent one of the most rapidly evolving areas of product development in the biopharmaceutical industry. Amgen’s Enbrel had been talked about as one of the first complex biologics likely to appear in a biosimilar form, with protection assumed to expire in late 2012 in the U.S. and in 2015 in Europe. On November 22, however, Amgen reported that a patent for the fusion protein that is Enbrel had just been extended by 17 years. Biosimilar companies with large stakes in antibody development, however, are still likely to challenge the ’182 patent or come up with ways to circumvent it. Who do you think will succeed?